Azzam Yazji, Erika Nicole Brown, Rodrigo De La Torre, Godsfavour Oghenero Umoru
INTRODUCTION: Immune checkpoint inhibitors (ICI) have changed the prognostic outlook for several malignancies. Despite the unprecedented durable responses and improvement in survival outcomes with ICIs, exclusion of oncology patients living with human immunodeficiency virus (HIV) from most ICI-related trials has limited utility of these agents. Clinical outcomes related to concomitant use of antiretroviral therapy and ICI remain unclear. We present a case series based on our institution's experience to address this unmet need of clinical outcomes with ICI in oncology patients living with HIV...
July 23, 2024: Journal of Oncology Pharmacy Practice
Elena Yaiza Romero-Ventosa, Nerea García-Beloso, Aida López-López, Noemí Martínez-López-de-Castro
INTRODUCTION: Pembrolizumab is currently the drug for the first-line treatment of stage-IV non-small cell lung cancer. The objective of this study is to measure the effectiveness of pembrolizumab as a first-line treatment and to analyze its safety in real clinical practice. METHODS: This was a retrospective study that included patients with metastatic non-small cell lung cancer who had received pembrolizumab as a first-line treatment between 1 June 2018 and 31 January 2021...
July 23, 2024: Journal of Oncology Pharmacy Practice
Lakshmi Balagopalan, Taylor Moreno, Haiying Qin, Benjamin C Angeles, Taisuke Kondo, Jason Yi, Katherine M McIntire, Neriah Alvinez, Sandeep Pallikkuth, Mariah E Lee, Hidehiro Yamane, Andy D Tran, Philippe Youkharibache, Raul E Cachau, Naomi Taylor, Lawrence E Samelson
Chimeric antigen receptor (CAR) T cells have been used to successfully treat various blood cancers, but adverse effects have limited their potential. Here, we developed chimeric adaptor proteins (CAPs) and CAR tyrosine kinases (CAR-TKs) in which the intracellular ζ T cell receptor (TCRζ) chain was replaced with intracellular protein domains to stimulate signaling downstream of the TCRζ chain. CAPs contain adaptor domains and the kinase domain of ZAP70, whereas CAR-TKs contain only ZAP70 domains...
July 23, 2024: Science Signaling
Daniel Terheyden-Keighley, Melanie Hühne, Thomas Berger, Björn Hiller, Soraia Martins, Anna Gamerschlag, Davood Sabour, Andrea Meffert, Andreas Kislat, Carsten Slotta, Francois Hafezi, Jens Lichte, Smita Sudheer, Karen Tessmer, Katherina Psathaki, Marius Ader, Gesine Kogler, Boris Greber
Cell therapeutic applications based on induced pluripotent stem cells (iPSCs) appear highly promising and challenging at the same time. Good manufacturing practice (GMP) regulations impose necessary yet demanding requirements for quality and consistency when manufacturing iPSCs and their differentiated progeny. Given the scarcity of accessible GMP iPSC lines, we have established a corresponding production workflow to generate the first set of compliant cell banks. Hence, these lines met a comprehensive set of release specifications and, for instance, displayed a low overall mutation load reflecting their neonatal origin, cord blood...
July 23, 2024: Stem Cells Translational Medicine
Jeffrey N Bryan, Charles A Maitz
Companion dogs have served an important role in cancer immunotherapy research. Sharing similar environments and diets with humans, dogs naturally develop many of the same cancers. These shared exposures, coupled with dogs' diverse genetic makeup, makes them ideal subjects for studying cancer therapies. Tumors like osteosarcoma (cOSA), hemangiosarcoma (cHSA), soft-tissue sarcoma (cSTS), and non-Hodgkin lymphoma (cnHL) occur with greater frequency than their counterpart disease in humans. Canine brain tumors allow study of therapy strategies with imaging, surgery, and radiotherapy equipment in veterinary patients with near-human geometry...
July 23, 2024: Clinical Cancer Research
Jianjian Yang, Ying Liu, Qing Geng, Bo Wang
No abstract text is available yet for this article.
July 23, 2024: Molecular Biology Reports
Ruixuan Guan, Yiling Lin, Cun Zhang, Zhao Wang, Zhiping Wu, Xiaojing Liu, Xin Chen, Yongjun Piao
Severe alopecia areata (AA) is a nonscarring hair loss for immune disorder and SALT score ≥ 50%. The guidelines for managing patients with severe AA suggest treatments: systemic steroids, JAK inhibitors, and contact immunotherapy. However, there is a lack of evidence indicating the superiority of one treatment over another. Therefore, this study aimed to identify the most effective treatment for severe AA through network meta-analysis. Following the PRISMA guidelines, we conducted a network meta-analysis...
July 23, 2024: Archives of Dermatological Research
(no author information available yet)
No abstract text is available yet for this article.
July 1, 2024: International Journal of Surgery
Rifat S Rahman, Duane R Wesemann
Despite the near ubiquitous presence of Ig-based antibodies in vertebrates, IgE is unique to mammals. How and why it emerged remains mysterious. IgE expression is greatly constrained compared to other IgH isotypes. While other IgH isotypes are relatively abundant, soluble IgE has a truncated half-life, and IgE plasma cells are mostly short-lived. Despite its rarity, IgE is consequential and can trigger life-threatening anaphylaxis. IgE production reflects a dynamic steady state with IgG memory B cells feeding short-lived IgE production...
July 23, 2024: Immunological Reviews
Anna Babayan, Evgeny Ledin, Alexandra Lebedeva, Olesya Kuznetsova, Daria Kravchuk, Tatiana Grigoreva, Ekaterina Belova, Alexandra Kavun, Vladislav Mileyko, Alexey Tryakin, Mikhail Fedyanin, Maxim Ivanov
Microsatellite instability (MSI) is an important biomarker in cancer. While routine methods can detect MSI in certain tumor types, in other tumor types the results may be incorrect due to differences in the MSI loci pattern. Here, we report the case of a patient with pancreatic adenocarcinoma, with confirmed MSI by two independent next-generation sequencing tests, but not by routine methods, who had progression on pembrolizumab. Comparison of the patient's MSI loci patterns with MSI+ colorectal adenocarcinoma samples showed a lower fraction of unstable loci, low resolution of a second peak in the repeat length spectrum of unstable short tandem repeats in the patient's sample, and a lower length of indels (3...
July 23, 2024: Immunotherapy
Chi Tonglien Viet, Michael Zhang, Neeraja Dharmaraj, Grace Y Li, Alexander T Pearson, Victoria A Manon, Anupama Grandhi, Ke Xu, Bradley E Aouizerat, Simon Young
Oral squamous cell carcinoma (OSCC) is a highly unpredictable disease with devastating mortality rates that have not changed over the past decades, in the face of advancements in treatments and biomarkers, which have improved survival for other cancers. Delays in diagnosis are frequent, leading to more disfiguring treatments and poor outcomes in patients. The clinical challenge lies in identifying those patients at highest risk for developing OSCC. Oral epithelial dysplasia (OED) is a precursor of OSCC with highly variable behavior across patients...
July 23, 2024: Tissue Engineering. Part A
Anni Su, Renhua Song, Justin J-L Wong
BACKGROUND: N7-methylguanosine (m7 G) modification is one of the most prevalent RNA modifications in humans. Dysregulated m7 G modifications caused by aberrant expression of m7 G writers contribute to cancer progression and result in worse patient survival in several human cancers. However, studies that systematically assess the frequency and clinical relevance of aberrant m7 G writer expression in a pan-cancer cohort remain to be performed. AIMS: This study aims to systematically investigate the molecular alteration and clinical relevance of m7 G methyltransferase in human cancers...
July 2024: Cancer reports
Yue Ma, Shiyun Chen, Guanghai Dai
Immunotherapy, led by programmed cell death protein-1 (PD-1) inhibitors, has emerged as a prominent antitumor therapy, yet prognostic challenges persist in pancreatic cancer (PC). This retrospective, single-center study evaluated prognostic factors in advanced PC patients treated with PD-1 inhibitors at the PLA General Hospital's Oncology Department from 2015-2022. With ethics approval by the Ethics Committee of the General Hospital of the People's Liberation Army (S2021-228-03), we analyzed 126 patients using Kaplan-Meier and Cox models...
December 31, 2024: Human Vaccines & Immunotherapeutics
Hanming Yao, Chengzhi Huang, Jinmao Zou, Weiling Liang, Yue Zhao, Kege Yang, Ziyi Zhong, Shurui Zhou, Jiajia Li, Yaqing Li, Lishu Xu, Kaihong Huang, Guoda Lian
Pancreatic ductal adenocarcinoma (PDAC) is characterised by immune evasion that contribute to poor prognosis. Cancer-associated fibroblasts (CAFs) play a pivotal role in orchestrating the PDAC tumour microenvironment. We investigated the role of CAF-derived extracellular vesicle (EV)-packaged long non-coding RNAs (lncRNAs) in immune evasion and explored gene therapy using engineered EVs loading small interfering RNAs (siRNAs) as a potential therapeutic strategy. Our findings highlight the significance of EV-packaged lncRNA RP11-161H23...
July 2024: Journal of Extracellular Vesicles
Yunhan Jiang, Xiaoqiu Xu, Dongmei Fan, Pingxian Liu, Meng Zhou, Mengdi Cheng, Jiasheng Huang, Youfu Luo, Yingqiang Guo, Tao Yang
Traditional antibody-drug conjugates (ADCs) mainly suppress tumor growth through either chemotherapy with cytotoxic payloads or immunotherapy with immuno-modulators. However, a single therapeutic modality may limit their exploration. Herein, we developed a new type of drug conjugate termed CAR-EDC (CAR-M-derived exosome-drug conjugate) by using CAR-exosomes from CAR-M cells as the targeting drug carrier that contains a high level of CXCL10. CAR-exosomes could significantly enhance the immunological activation and migratory capacity of T lymphocytes and promote their differentiation into CD8+ T cells...
July 23, 2024: Journal of Medicinal Chemistry
Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber
Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 antibody fusion protein designed for selective IL-2 receptor βγ (IL-2 Rβγ) activation by sterically hindering IL-2 from binding to IL-2 Rα. The fusion protein has an IL-2 connected to the light chain complementarity-determining region (CDR) domain of a humanized antibody that binds to IL-2 at the same epitope as IL-2 Rα...
2024: MAbs
Rémi Vernet, Eugenio Fernandez, Denis Migliorini, Virginie Ancrenaz, Emily Charrier, Marie-Claude Belkouch, Olivier Von Rohr, Muriel Urwyler, Claudio De Vito, Jessica Renaux, Jean Villard, Olivier Rubin, Julien Grogg, Nicolas Mach
Purpose Over two decades, most cancer vaccines failed clinical development. Key factors may be the lack of efficient priming with tumor-specific antigens and strong immunostimulatory signals. MVX-ONCO-1, a personalized cell-based cancer immunotherapy, addresses these critical steps utilizing clinical-grade material to replicate a successful combination seen in experimental models: inactivated patient's own tumor cells, providing the widest cancer-specific antigens repertoire and a standardized, sustained, local delivery over days of a potent adjuvant achieved by encapsulated cell technology...
July 23, 2024: Cancer Res Commun
Xin-Hao Tang, Bo-Wen Chu, Chen-Tian-Yi Li, Ying-Fei Wang, Zhong-Hui Xia, Zi-Mo Li, Xin-Yu Tian, Cong-Ying Wang, Qi Chen, Shuai Hao, Wei Tao, Jian-Ming Wang, Mian-Hua Wu, Xiao-Hong Zheng
According to the theory of five movements and six climates, the innate constitution plays a crucial role in determining the underlyingpa thological mechanisms of diseases later in life. Previous studies have demonstrated a close association between the constitution, as defined by the theory of five movements and six climates, and the development of various types of tumors. Furt hermore,the tumorsubtype determined by the constitution has prognostic implications. This highlights the potential of utilizing the fivemovements and six climates theory to guide the implementation of precision medicine strategies in thefield of oncology...
June 2024: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
Camélia Benhayoun, Anne Bénédicte Duval Modeste, Clémence Tamarit, Pascal Joly, Raphaël Janela-Lapert
No abstract text is available yet for this article.
August 2024: JAAD Case Reports
Yundi Chen, Shasha Tang, Fengfeng Cai, Yuan Wan
Extracellular vesicles (EVs) are lipid bilayer-enclosed vesicles released by cells. EVs encapsulate proteins and nucleic acids of their parental cell and efficiently deliver the cargo to recipient cells. These vesicles act as mediators of intercellular communication and thus play a crucial role in various physiological and pathological processes. Moreover, EVs hold promise for clinical use. They have been explored as drug delivery vehicles, therapeutic agents, and targets for disease diagnosis. In the landscape of cancer research, while strides have been made in EV-focused cancer physiopathology, liquid biopsy, and drug delivery, the exploration of EVs as immunotherapeutic agents may not have seen substantial progress to date...
2024: Research: a science partner journal
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.